The costs and benefits of community thrombolysis for acute myocardial infarction: A decision-analytic model

PharmacoEconomics

Volumn 22, Issue 14, 2004, Pages 943-954

  Vale, Luke ^a   Steffens, Harvey ^a,b   Donaldson, Cam ^a,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MINISTRY OF HEALTH   (New Zealand)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; FIBRINOLYTIC AGENT; HEPARIN; MORPHINE; STREPTOKINASE;

ARTICLE; BLOOD CLOT LYSIS; COMMUNITY CARE; COST BENEFIT ANALYSIS; DRUG COST; FOLLOW UP; HEALTH CARE COST; HEART INFARCTION; HOSPITAL CARE; LIFE EXPECTANCY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; UNITED KINGDOM;

ANISTREPLASE; CARDIAC CARE FACILITIES; COHORT STUDIES; COMMUNITY HEALTH SERVICES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; FIBRINOLYTIC AGENTS; GREAT BRITAIN; HEPARIN; HOSPITALIZATION; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; STREPTOKINASE; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY;

EID: 6044244687     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422140-00004     Document Type: Article

References (27)

1. Farkouh ME, Lang JD, Sackett DL. Thrombolytic agents: the science of the art of choosing the better treatment. Ann Intern Med 1994; 120: 886-8
2. GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; I: 397-401
3. GREAT Group. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian Region Early Anistreplase Trial. BMJ 1992; 305: 548-53
4. Rawles J. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1994; 23 (1): 1-5
5. Rawles J. Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian Region Early Anistreplase Trial (GREAT). BMJ 1996; 312: 212-5
6. ISIS-3, ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70
7. Netten A, Rees T, Harris G. Unit costs of community care. PSSRU: University of Kent, 2001
8. Review Body on Doctors' and dentists' remuneration. Twenty fourth report (1995): The Stationery Office Limited. London: 1995
9. British National Formulary. London: British Medical Association and The Pharmaceutical Press, 2001
10. Scottish health service costs, year ended 31st March 2001. Common Services Agency, Information and Statistics Division, 2001 Aug
11. Rowley JM, Mounser P, Harrison EA, et al. Management of myocardial infarction: implications for current policy derived from the Nottingham Heart Attack Register. Br Heart J 1992; 67 (3): 255-62
12. French JK, Williams BF, Hart HH, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ 1996; 312: 1637-41
13. Hillegass WB, Jollis JG, Granger CB, et al. Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction. Am J Cardiol 1994; 73 (7): 444-9
14. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,817 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; II: 349-60
15. Rawles JM. Recovery of left ventricular function after acute myocardial infarction: efficacy of domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial. Coron Artery Dis 1993; 4 (9): 801-8
16. Kowalenko T, Kereiakis D, Gibler W. Prehospital diagnosis and treatment of myocardial infarction: a critical review. Am Heart J 1992; 123 (1): 181-90
17. Hannaford P, Vincent R, Ferry S, et al. Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners. Br J Gen Pract 1995; 45 (393): 175-9
18. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"), I validation of the method. Am J Med 1982; 73: 883-8
19. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"), II use in medical decision making. Am J Med 1982; 73: 889-97
20. Martens L, van Doorslaer E. Dealing with discounting, an application to the cost-effectiveness of intracoronary thrombolysis with streptokinase. Int J Technol Assess Health Care 1990; 6: 139-45
21. Vermeer F, Simoons M, de Zwaan C, et al. Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase, twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of the Netherlands. Br Heart J 1988; 59: 527-34
22. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol 1979; 44: 53-9
23. Merrilees MA, Scott PJ, Norris MN. Prognosis after myocardial infarction: results of 12 year follow up. BMJ 1984; 288: 356-9
24. Martin C, Thompson P, Armstrong B, et al. Long term prognosis after recovery from myocardial infarction: a nine year follow-up of the Perth Coronary Register. Circulation 1983; 68: 961-9
25. Registrar General. Life tables 1990-1992. First supplement to the hundred and thirty third annual report of the Registrar General for Scotland. Edinburgh: Her Majesty's Stationery Office, 1998
26. Cucherat M, Bonnefoy E, Tremeau G. Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2003
27. Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) Study Group, Bonnefoy E, Lapostolle F, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360: 825-9